Cao Meng, Wang Jikun, Yao Lu, Xie Suhua, Du Jing, Zhao Xingbo
National Engineering Laboratory for Animal Breeding, Ministry of Agricultural Key Laboratory of Animal Genetics, Breeding and Reproduction, College of Animal Science and Technology, China Agricultural University, Beijing, 100193, China.
Mol Biol Rep. 2014;41(4):2485-91. doi: 10.1007/s11033-014-3105-x. Epub 2014 Jan 21.
Lingyang Qingfei Wan produced by Beijing TongRenTang is a long-standing and popular medicine in China and international pharmaceutical markets. Concerns continue to be raised about the legality of usage of saiga antelope, which was defined as endangered species by Convention on International Trade in Endangered Species of Wild Fauna and Flora legislation and internal legislation in China. Therefore, the alternative pill in which substitutes saiga antelope with goat in the formula of Lingyang Qingfei Wan was developed. In order to authenticate the origin of animal contents in Lingyang Qingfei Wan and its alternative pill, molecular diagnostic assay was utilized by mtDNA polymorphism analysis. Four universal primer pairs containing mtDNA 12SrRNA, 16SrRNA, cytochrome b gene and cytochrome oxidase I were employed to obtain species-specific sequences of saiga antelope and goat, and multiple species-specific primer pairs for saiga antelope and goat were used to identify the animal origin in patent pills according to nucleotide polymorphisms between the two species. In additions, alternative techniques were attempted surrounding dilemmas of low concentration of target DNAs and presence of PCR-inhibitory substances in organic ingredients within complex pill. Results revealed that all species-specific primers could be successfully used for authentication of animal origin within complex pill, and sample preprocessing was critical during experimental manipulation. Internal positive control was an efficient and cost-effective way to assist in monitoring the potential interference from inhibitory substances which existed in the highly processed pills.
北京同仁堂生产的羚羊清肺丸在中国及国际医药市场上都是一种历史悠久且广受欢迎的药品。由于藏羚羊被《濒危野生动植物种国际贸易公约》及中国国内立法界定为濒危物种,其使用的合法性一直备受关注。因此,开发了一种在羚羊清肺丸配方中用山羊替代藏羚羊的替代丸剂。为了鉴定羚羊清肺丸及其替代丸剂中动物成分的来源,利用线粒体DNA多态性分析进行分子诊断检测。使用了四对包含线粒体DNA 12SrRNA、16SrRNA、细胞色素b基因和细胞色素氧化酶I的通用引物对,以获得藏羚羊和山羊的物种特异性序列,并根据这两个物种之间的核苷酸多态性,使用多对藏羚羊和山羊的物种特异性引物对来鉴定专利丸剂中的动物来源。此外,针对复杂丸剂中有机成分中目标DNA浓度低和存在PCR抑制物质的难题,尝试了其他技术。结果表明,所有物种特异性引物均可成功用于复杂丸剂中动物来源的鉴定,且样品预处理在实验操作过程中至关重要。内部阳性对照是一种有效且经济高效的方法,有助于监测高度加工丸剂中存在的抑制物质的潜在干扰。